High-Dose Cytosine Arabinoside in Chronic Lymphocytic Leukemia: A Clinical and Pharmacologic Analysis

References

• Velasquez W., Cabanillas F., McLaughlin P., Plunkett W., Hagemeister F., Swan F., Reireich E. J. Combination of cisplatin,4 ara-C and decadron in relapsing lymphoma. Proceedings of the American Society of Clinical Oncology 1986; 5: 191, (abstr)
   Google Scholar
• Keating M. J., Scouros M., Kantarjian H., Hester J., McCredie K. B., Hersh E. M., Freireich E. J. Multiple agent chemotherapy (POACH) in previously treated and untreated patients with chronic lymphocytic leukemia. Leukemia 1988; 2: 157–64
   PubMed Web of Science ®Google Scholar
• Barton J. H., Capizzi R. L., Spurr C. L., Brockschmidt J. High dose ara-C (Hidac) and asparaginase (A'ase) in refractory chronic lymphocytic leukemia. Proceedings of the American Society of Clinical Oncology 1990; 9: 205, (abstr)
   Google Scholar
• McCroskey R. D., Mosher D. F., Spencer C. D., Prendergast E., Longo W. L. Acute tumor lysis syndrome and treatment response in patients treated for refractory chronic lymphocytic leukemia with short-course, high-dose cytosine arabinoside, cisplatin, and etoposide. Cancer 1990; 66: 246–50
   PubMed Web of Science ®Google Scholar
• De Rossi G., Mauro F. R., Pizzo F., Coluzzi S., Luciani M., Mandelli F. Combination of cytosine-arabinoside (ara-C), cyclophosphamide and prednisone in the treatment of B-chronic lymphocytic leukemia in advanced stages and progressive disease. Leukemia and Lymphoma 1991, Suppl: 101–103
   PubMed Web of Science ®Google Scholar
• Nagourney R. A., Link J., Schlutz M., Weisenthal L. M. Cytarabine (ARAC) activity in chronic lymphophocytic leukemia (CLL): laboratory observation with potential clinical applications. Proceedings of the American Society of Clinical Oncology 1991; 10: 229, (abstr)
   Google Scholar
• Cheson B. D., Bennett J. M., Rai K. R., Grever M. R., Kay N. E., Schiffer C. A., Oken M. M., Keating M. J., Boldt D. H., Kempin S. J., Foon K. A. Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-Sponsored Working Group. American Journal of Hematology 1988; 29: 152–63
   PubMed Web of Science ®Google Scholar
• Plunkett W., Chubb S., Barlogie B. Simultaneous determination of 1-β-arabinofuranosylcytosine 5'-triphosphate and 3-deazauridine S'-triphosphate in human leukemia cells by high performance liquid chromatography. Journal of Chromatography 1980; 221: 425–30
   PubMed Web of Science ®Google Scholar
• Kempin S., Lee B. J., Thaler H. T. Combination chemotherapy of advanced chronic lymphocytic leukemia: the M-2 protocol (vincristine, BCNU, cyclophosphamide, melpha-lan, and prednisone). Blood 1982; 60: 1110–21
   PubMed Web of Science ®Google Scholar
• Montserrat E., Alcala A., Parody R. Treatment of chronic lymphocytic leukemia in advanced stages: a randomized trial comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine, and prednisone. Cancer 1985; 56: 2369–75
   PubMed Web of Science ®Google Scholar
• Oken M. E., Kaplan M. D. Combination chemotherapy with cyclophosphamide, vincristine, and prednisone in the treatment of refractory chronic lymphocytic leukemia: prognostic significance. Cancer 1977; 40: 855–64
   PubMed Web of Science ®Google Scholar
• Sawitsky A., Rai K. R., Glidewell O., Silver R. T. Cancer and Leukemia Group B. Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia. Blood 1977; 50: 1049–59
   PubMed Web of Science ®Google Scholar
• Keating J., Kantarjian H., Talpaz M., Redman J., Koller C., Barlogie B., Velasquez W., Plunkett W., Freireich E. J., McCredie K. B. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood 1989; 74: 19–25
   PubMed Web of Science ®Google Scholar
• Kantarjian H. M., Estey E. H., Plunkett W., Keating M. J., Walters R. S., Iacoboni S., McCredie K. B., Freireich E. J. Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia. The American Journal of Medicine 1986; 81: 387–94
   PubMed Web of Science ®Google Scholar
• Estey E., Plunkett W., Dixon D., Keating M., McCredie K., Friereich E. J. Variables predicting response to high dose cytosine arabinoside therapy in patients with refractory acute leukemia. Leukemia 1987; 1: 580–83
   PubMed Web of Science ®Google Scholar
• Estey E., Keating M., McCredie K., Freireich E. J., Plunkett W. Cellular ara-CTP pharmacokinetics, response, and karyotype in newly diagnosed acute myelogenous leukemia. Leukemia 1990; 4: 95–9
   PubMed Web of Science ®Google Scholar
• Robertson L. E., Chubb S., Meyn R. E., Story M., Ford R., Hittelman W. N., Plunkett W. Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2'- deoxyadenosine and 9-β-D-arabinosyl-2-fluoro-adenine. Blood 1992; 81: 143–150
   Web of Science ®Google Scholar
• Iacoboni S. J., Plunkett W., Kantarjian H. M., Estey E., Keating M. J., McCredie K. B., Freireich E. J. High-dose cytosine arabinoside: treatment and cellular pharmacology of chronic myelogenous leukemia blastic crisis. Journal of Clinical Oncology 1986; 4: 1079–88
   PubMed Web of Science ®Google Scholar
• Liliemark J. O., Plunkett W. Regulation of 1-β-D-arabinofuranosylcytosine5'- triphosphate accumulation in human leukemia cells by deoxycytidine 5'- triphosphate. Cancer Res. 1986; 46: 1079–83
   PubMed Web of Science ®Google Scholar
• Gandhi V., Plunkett W. Cell cycle-specific metabolism of arabinosylnucleosides in K562 human leukemia cells. Cancer Chemother Pharmacol 1992; 31: 11–17
   PubMed Web of Science ®Google Scholar
• Ho D. H. W. Distribution of kinase and deaminase of l-/3-D-arabinofuranosylcytosine in tissue of man and mouse. Cancer Res 1973; 33: 2815–20
   Google Scholar
• Burgess F. W., Kouni M. H., Parks R. E., Jr. Nucleotidase activities of human peripheral lymphocytes. Biochem Pharmacol 1985; 17: 3061–70
   Web of Science ®Google Scholar